Pear Therapeutics, Inc. — Department of Health and Human Services SBIR Phase I: NIDA
Pear Therapeutics, Inc. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $180,053
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- NIDA
- Solicitation
- PA16-302
- NAICS
- —
- Place of performance
- MA
- Period
- 2017-07-01 → 2018-05-31
Description
Abstract Summary Opioid Use Disorder OUD is a serious public health concern that affected million Americans and was responsible for a record number of overdose deaths in Remarkably of individuals with OUD do not receive treatment even though OUD can be successfully treated when cognitive behavioral therapy is combined with buprenorphine pharmacotherapy A major barrier to receiving care is limited access to providers For those who do seek treatment high rates of attrition and lack of medication adherence limit the effectiveness of care There is an urgent need for treatment solutions that address these problems The goal of Pear Therapeutics Fast Track proposal is to develop a widely accessible game based behavioral therapy for OUD that improves patient engagement and supports medication compliance This solution named Options and Outcomes Oandamp O is a mobile application designed to supplement standard face to face OUD behavioral therapy Oandamp O will be modeled on Pear s current digital intervention for Substance Use Disorder reSET a clinically validated digital therapy that significantly improves clinical outcomes Although effective reSET s curriculum is primarily delivered using narrative text Building a more interactive and appealing product to deliver the same educational content has the potential to increase patient engagement and enhance learning Oandamp O will be a role playing game that requires active participation patients will interact with the main characters guiding their decision making process as they learn and deploy key concepts taught during the game Newly developed content and features will emphasize the important role of buprenorphine in recovery and support medication adherence This proposal is an innovative evolution from previous systems Oandamp O will deliver validated therapeutic content in in a unique and effective way that is not currently possible Pear s long term goal is to help individuals with OUD achieve lasting recovery by creating effective and accessible digital therapies The first phase of this proposal will focus on developing and test a functional Oandamp O prototype using proven videogame techniques to maximize patient engagement and leveraging digital capabilities to support buprenorphine adherence Phase II efforts will expand and validate the Oandamp O intervention Phase IIa will use iterative patient feedback to incorporate reSET s core curriculum into an immersive game environment that is realistic and relevant A small randomized control trial comparing Oandamp O to reSET will evaluate patient engagement learning and efficacy in Phase IIb Oandamp O will provide an innovative approach for OUD treatment that addresses shortcomings in the current standard of care such as access buprenorphine adherence and patient retention Oandamp O will be marketed to OUD treatment centers as an off the shelf digital application that can enhance standard therapy Given the number of individuals in need of accessible treatment options for OUD there is a substantial market for Oandamp O Project Narrative The US is currently facing an opioid epidemic millions of Americans are dependent on or abuse opioids and opioid related overdose deaths hit record levels in Although Opioid Use Disorder can be effectively treated when behavioral therapy is combined with buprenorphine pharmacotherapy lack of medication adherence and high attrition rates for those who do seek treatment limit the effectiveness of care To help address this crisis Pear Therapeutics will develop and validate a mobile application that uses an interactive game environment to deliver effective behavioral therapy and support buprenorphine compliance helping patients achieve lasting recovery by more actively engaging them in treatment